Literature DB >> 20023923

Nuclear targets of photodynamic tridentate ruthenium complexes.

Ran Zhao1, Richard Hammitt, Randolph P Thummel, Yao Liu, Claudia Turro, Robert M Snapka.   

Abstract

Octahedral ruthenium complexes, capable of photodynamic singlet oxygen production at near 100% efficiency, were shown to cause light-dependent covalent crosslinking of p53 and PCNA subunits in mammalian cells and cell lysates. Azide, a singlet oxygen quencher, greatly reduced the p53 photocrosslinking, consistent with the idea that singlet oxygen is the reactive oxygen species involved in p53 photocrosslinking. A photodynamically inactive ruthenium complex, [Ru(tpy)(2)](2+) (tpy = [2,2';6',2'']-terpyridine), had no effect on p53 or PCNA photocrosslinking. Photodynamic damage to p53 has particular relevance since p53 status is an important determinant of phototoxicity and the effectiveness of photodynamic cancer therapy. The two photodynamic complexes studied, [Ru(tpy)(pydppn)](2+), where pydppn = (3-(pyrid-2'-yl)-4,5,9,16-tetraaza-dibenzo[a,c]naphthacene, and [Ru(pydppn)(2)](2+), differed in their efficiency of p53 and PCNA photocrosslinking in cells, but showed similar efficiency of photocrosslinking in cell lysates, suggesting that they differ in their ability to enter cells. Photocrosslinking of PCNA by [Ru(tpy)(pydppn)](2+) increased linearly with concentration, time of uptake, or light exposure. Both [Ru(tpy)(pydppn)](2+) and [Ru(pydppn)(2)](2+) caused photodynamic protein-DNA crosslinking in cells, but [Ru(tpy)(pydppn)](2+) was more efficient. The efficiency of photodynamic protein-DNA crosslinking by [Ru(tpy)(pydppn)](2+) in cells increased with increasing levels of photodynamic damage. Photodynamic damage by [Ru(tpy)(pydppn)](2+) caused inhibition of DNA replication in a classical biphasic response, suggesting that DNA damage signaling and cell cycle checkpoint pathways were still operative after significant damage to nuclear proteins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20023923     DOI: 10.1039/b913959a

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  12 in total

1.  To intercalate or semiintercalate, or both?

Authors:  Claudia Turro
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-13       Impact factor: 11.205

2.  Control and utilization of ruthenium and rhodium metal complex excited states for photoactivated cancer therapy.

Authors:  Jessica D Knoll; Claudia Turro
Journal:  Coord Chem Rev       Date:  2015-01-01       Impact factor: 22.315

3.  [Ru(bpy)2(5-cyanouracil)2]2+ as a potential light-activated dual-action therapeutic agent.

Authors:  Robert N Garner; Judith C Gallucci; Kim R Dunbar; Claudia Turro
Journal:  Inorg Chem       Date:  2011-08-31       Impact factor: 5.165

4.  Nicotine mediates hypochlorous acid-induced nuclear protein damage in mammalian cells.

Authors:  Samir A Salama; Hany H Arab; Hany A Omar; Ibrahim A Maghrabi; Robert M Snapka
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

Review 5.  The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.

Authors:  Leli Zeng; Pranav Gupta; Yanglu Chen; Enju Wang; Liangnian Ji; Hui Chao; Zhe-Sheng Chen
Journal:  Chem Soc Rev       Date:  2017-10-02       Impact factor: 54.564

6.  Metalloimmunotherapy with Rhodium and Ruthenium Complexes: Targeting Tumor-Associated Macrophages.

Authors:  Nicholas Toupin; Mackenzie K Herroon; Randolph P Thummel; Claudia Turro; Izabela Podgorski; Heather Gibson; Jeremy J Kodanko
Journal:  Chemistry       Date:  2022-03-24       Impact factor: 5.020

7.  [Ru(Me4phen)2dppz](2+), a Light Switch for DNA Mismatches.

Authors:  Adam N Boynton; Lionel Marcélis; Jacqueline K Barton
Journal:  J Am Chem Soc       Date:  2016-04-12       Impact factor: 15.419

8.  Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433.

Authors:  Susan Monro; Katsuya L Colón; Huimin Yin; John Roque; Prathyusha Konda; Shashi Gujar; Randolph P Thummel; Lothar Lilge; Colin G Cameron; Sherri A McFarland
Journal:  Chem Rev       Date:  2018-10-08       Impact factor: 60.622

9.  New Ru(ii) complex for dual photochemotherapy: release of cathepsin K inhibitor and 1O2 production.

Authors:  Thomas N Rohrabaugh; Kelsey A Collins; Congcong Xue; Jessica K White; Jeremy J Kodanko; Claudia Turro
Journal:  Dalton Trans       Date:  2018-08-29       Impact factor: 4.390

Review 10.  Photoactivatable metal complexes: from theory to applications in biotechnology and medicine.

Authors:  Nichola A Smith; Peter J Sadler
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2013-06-17       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.